BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20042512)

  • 1. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
    Ofek G; McKee K; Yang Y; Yang ZY; Skinner J; Guenaga FJ; Wyatt R; Zwick MB; Nabel GJ; Mascola JR; Kwong PD
    J Virol; 2010 Mar; 84(6):2955-62. PubMed ID: 20042512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
    Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
    J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.
    Chen J; Frey G; Peng H; Rits-Volloch S; Garrity J; Seaman MS; Chen B
    J Virol; 2014 Jan; 88(2):1249-58. PubMed ID: 24227838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
    Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
    J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J; Wyatt RT
    PLoS Pathog; 2012; 8(7):e1002806. PubMed ID: 22829767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
    Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
    J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
    Rujas E; Gulzar N; Morante K; Tsumoto K; Scott JK; Nieva JL; Caaveiro JM
    J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.
    Lutje Hulsik D; Liu YY; Strokappe NM; Battella S; El Khattabi M; McCoy LE; Sabin C; Hinz A; Hock M; Macheboeuf P; Bonvin AM; Langedijk JP; Davis D; Forsman Quigley A; Aasa-Chapman MM; Seaman MS; Ramos A; Poignard P; Favier A; Simorre JP; Weiss RA; Verrips CT; Weissenhorn W; Rutten L
    PLoS Pathog; 2013 Mar; 9(3):e1003202. PubMed ID: 23505368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
    J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    Ou W; Lu N; Yu SS; Silver J
    J Virol; 2006 Mar; 80(5):2539-47. PubMed ID: 16474160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
    Serrano S; Araujo A; Apellániz B; Bryson S; Carravilla P; de la Arada I; Huarte N; Rujas E; Pai EF; Arrondo JLR; Domene C; Jiménez MA; Nieva JL
    J Biol Chem; 2014 Mar; 289(10):6565-6580. PubMed ID: 24429284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.
    Kim M; Sun ZY; Rand KD; Shi X; Song L; Cheng Y; Fahmy AF; Majumdar S; Ofek G; Yang Y; Kwong PD; Wang JH; Engen JR; Wagner G; Reinherz EL
    Nat Struct Mol Biol; 2011 Oct; 18(11):1235-43. PubMed ID: 22002224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
    Alam SM; Liao HX; Dennison SM; Jaeger F; Parks R; Anasti K; Foulger A; Donathan M; Lucas J; Verkoczy L; Nicely N; Tomaras GD; Kelsoe G; Chen B; Kepler TB; Haynes BF
    J Virol; 2011 Nov; 85(22):11725-31. PubMed ID: 21917975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
    Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
    PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
    Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
    J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
    Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
    J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.